theflyonthewall
On Sunday June 5, 2011, 1:02 pm EDT
SciClone Pharmaceuticals announced new data from preclinical studies of SCV-07, the Company's lead development product candidate, which showed that the compound successfully inhibited the growth of a variety of tumor cell lines in mice. These results suggest that the use of SCV-07 as a treatment for oral mucositis (OM) in patients with a variety of cancers should not interfere with the antitumor effects of primary cancer therapy, but may in fact enhance the tumor response of conventional therapy. Additionally, SciClone researchers have identified potential molecular and cellular mechanisms by which SCV-07 may be able to inhibit both mucositis and tumor progression. These data are being presented today in two poster presentations at the 2011 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM